<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; TG</title>
	<atom:link href="http://www.stockbloghub.com/tag/tg/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Expands Pipeline</title>
		<link>http://www.stockbloghub.com/2010/01/18/isis-isis-pharmaceuticals-expands-pipeline/25201</link>
		<comments>http://www.stockbloghub.com/2010/01/18/isis-isis-pharmaceuticals-expands-pipeline/25201#comments</comments>
		<pubDate>Tue, 19 Jan 2010 00:17:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[TG]]></category>
		<category><![CDATA[Tredegar Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25201</guid>
		<description><![CDATA[Isis Pharmaceuticals, Inc. (ISIS) is working on expanding its cardiovascular pipeline. The company recently announced that it has added a new drug, ISIS-APOCIIIRx, to its development pipeline. The candidate is being studied for the treatment of hypertriglyceridemia, or high levels of triglycerides (TG). Hypertriglyceridemia is an independent risk factor for cardiovascular disease and is also a trait of metabolic syndrome, which occurs in a large percentage of people with type II diabetes. ISIS-APOCIIIRx is the third new drug to be added to the company&#8217;s pipeline recently. Over the past few months, the company has been working on expanding its pipeline. In early December 2009, the company added two new drugs to its pipeline &#8211; ISIS-FXIRx and ISIS-SMNRx. While ISIS-FXIRx is designed to treat clotting disorders without increased risk of bleeding, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/18/isis-isis-pharmaceuticals-expands-pipeline/25201/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TG) Tredegar Corp. &#8211; Aggressive Growth &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/04/14/tg-tredegar-corp-aggressive-growth-zacks-rank-buy/5477</link>
		<comments>http://www.stockbloghub.com/2009/04/14/tg-tredegar-corp-aggressive-growth-zacks-rank-buy/5477#comments</comments>
		<pubDate>Tue, 14 Apr 2009 19:26:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aluminum]]></category>
		<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[TG]]></category>
		<category><![CDATA[Tredegar Corp.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5477</guid>
		<description><![CDATA[Tredegar Corp. (TG) recently shocked Wall Street with its latest earnings report. Shares are climbing as the stock hits a critical level. Company Description Tredegar Industries, Inc. is engaged in the manufacturing of plastic films, vinyl extrusions and aluminum extrusions. The company also has interests in various technologies Incorporatedluding rational drug design research and computer software. Tredegar&#8217;s materials are primarily for personal and household care products, and packaging and surface protection applications. The company has operations in North America, South America, Europe, and Asia. EPS Almost Double Consensus On Feb 12 Tredegar announced its forth-quarter results that included earnings per share of 30 cents, nearly double the 16 cents estimated by analysts. Income from continuing manufacturing operations was up $10.2 million, up 62% from $6.3 million. Estimates Are Up Full-year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/14/tg-tredegar-corp-aggressive-growth-zacks-rank-buy/5477/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

